Forge, Hoffman-La Roche partner on antibiotic for lung infections
Forge Therapeutics announced today that it will partner with Hoffman-La Roche to develop and commercialize a novel antibiotic for treating serious lung infections caused by antibiotic-resistant gram-negative bacteria.
The antibiotic, developed by Forge through its Fg-LpxC LUNG program, targets and inhibits LpxC, a zinc metalloenzyme found in gram-negative bacteria, using a proprietary chemistry platform.